1 |
Kamar N, Legrand-Abravanel F, Izopet J, et al. Hepatitis E virus: what transplant physicians should know[J]. Am J Transplant, 2012, 12(9): 2281-2287.
|
2 |
Darstein F, Häuser F, Mittler J, et al. Hepatitis E is a rare finding in liver transplant patients with chronic elevated liver enzymes and biopsy-proven acute rejection[J]. Transplant Proc, 2020, 52(3): 926-931.
|
3 |
Celik F, Senkaya A, Gulsen Unal N, et al. Hepatitis E virus IgG seroprevalence in liver transplant patients: A retrospective single-center experience[J]. Hepatol Forum, 2021, 2(1):7-11.
|
4 |
Abravanel F, Chapuy-Regaud S, Lhomme S, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients[J]. J Clin Virol, 2013, 58(4):624-628.
|
5 |
Fischler B, Baumann U, Dezsofi A, et al. Hepatitis E in children: a position paper by the ESPGHAN Hepatology Committee[J]. J Pediatr Gastroenterol Nutr, 2016, 63(2):288-294.
|
6 |
Coilly A, Haïm-Boukobza S, Roche B, et al. Posttransplantation hepatitis E: transfusion- transmitted hepatitis rising from the ashes[J]. Transplantation, 2013, 96(2):e4-e6.
|
7 |
Inagaki Y, Oshiro Y, Tanaka T, et al. A nationwide survey of Hepatitis E virus infection and chronic hepatitis E in liver transplant recipients in Japan[J]. EBioMedicine, 2015, 2(11):1607-1612.
|
8 |
Féray C, Pawlotsky JM, Roque-Afonso AM, et al. Should we screen blood products for hepatitis E virus RNA?[J]. Lancet, 2014, 383(9913):218.
|
9 |
Schlosser B, Stein A, Neuhaus R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient[J]. J Hepatol, 2012, 56(2):500-502.
|
10 |
Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England[J]. Lancet, 2014, 384(9956): 1766-1773.
|
11 |
Abi Nader E, Girard M, Leruez-Ville M, et al. Seroprevalence of hepatitis E virus infection in children after liver transplantation: a single-center experience in France[J]. Hepatol Gastroenterol, 2020, 44(2):174-180.
|
12 |
De Winter BCM, Hesselink DA, Kamar N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients[J]. Pharmacol Res, 2018,130:308-315.
|
13 |
Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural historyand therapy[J]. Semin Liver Dis, 2013, 33(1):62-70.
|
14 |
Belbézier A, Deroux A, Sarrot-Reynauld F, et al. Screening of hepatitis E in patients presenting for acute neurological disorders[J].J Infect Public Health, 2020, 13(7):1047-1050.
|
15 |
Webb GW, Dalton HR. Hepatitis E: an expanding epidemic with a range of complications. Clin Microbiol Infect[J]. 2020, 26(7):828-832.
|
16 |
Abravanel F, Lhomme S, Chapuy-Regaud S, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections[J]. J Infect Dis, 2014, 209(12):1900-1906.
|
17 |
Schulz M, Choi M, Bachmann F, et al. Shear wave elastography-based liver fibrosis assessment in patients with chronic hepatitis E displays elevated liver stiffness regardless of previous antiviral therapy[J]. Quant Imaging Med Surg, 2022, 12(7):3528-3538.
|
18 |
Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation[J]. Transplantation, 2010,89(3):353-360.
|
19 |
Buganza-Torio E, Doucette KE. Management of viral hepatitis in solid organ transplant recipients[J]. Infect Dis Clin North Am, 2018, 32(3):635-650.
|
20 |
Mazzola A, Tran Minh M, Charlotte F, et al. Chronic hepatitis E viral infection after liver transplantation: a regressionof fibrosis after antiviral therapy[J]. Transplantation, 2017, 101(9):2083-2087.
|
21 |
Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients[J]. N Engl J Med, 2014, 370(12):1111-1120.
|
22 |
Carter M, Solsrud K, Yeddula S, et al. Hepatitis E diagnosis and management after liver, kidney, or heart transplant: a single-center experience[J]. 2022, 54(7):1737-1741.
|
23 |
Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients[J]. Gastroenterology, 2014, 147(5):1008-1011.
|
24 |
Cheung CKM, Wong SH, Law AWH, et al. Transfusion-transmitted hepatitis E: what we know so far?[J]. World J Gastroenterol, 2022, 28(1):47-75.
|
25 |
Zhang J, Zhang XF, Huang SJ, et al. Long-term efficacy of a hepatitis E vaccine[J]. N Engl J Med, 2015, 372(10):914-922.
|
26 |
Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus[J]. Gastroenterology, 2014, 146(7):1775-1783.
|
27 |
Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants[J]. Gastroenterology, 2011, 140(5):1481-1489.
|
28 |
Markakis GE, Papatheodoridis GV, Cholongitas E. Epidemiology and treatment of hepatitis E in the liver transplantation setting: a literature review[J]. J Viral Hepat, 2022, 29(9):698-718.
|